Viz RV/LV vs EchoNext

Viz RV/LV is a seamless component of the broader Viz PE Solution, which includes AI-powered alerts, a high-fidelity mobile DICOM image viewer, and a HIPAA-compliant communication platform for care coordination. This integrated approach suggests a more streamlined and comprehensive user experience for clinicians managing pulmonary embolism cases. EchoNext is available through the OpenEvidence platform, but its direct user experience details are less elaborated, focusing more on its diagnostic capabilities.

EchoNext demonstrates superior clinical value by detecting a broader range of hidden structural heart diseases (heart failure, valve disease, pulmonary hypertension) from a standard ECG, often outperforming cardiologists in accuracy. This allows for earlier detection and intervention for conditions that might otherwise go undiagnosed until symptomatic. Viz RV/LV provides a crucial RV/LV ratio for pulmonary embolism risk stratification, which is valuable, but its scope is more focused on a specific acute condition.

EchoNext offers transparent tiered pricing starting at $600/month, with details on implementation fees and annual discounts, making its cost structure clear to potential customers. Viz RV/LV's pricing is not publicly available, which makes it difficult to assess its value proposition without direct inquiry. While both tools offer significant clinical value, EchoNext's transparent pricing provides a clearer understanding of the financial commitment.

Viz.ai's platform, of which Viz RV/LV is a part, is deployed across more than 1,200 health systems in the US and EMEA, indicating robust enterprise-level integration and scalability. It also boasts SOC 2 Type II and HIPAA compliance, with transparent access to security documentation. EchoNext is available through the OpenEvidence platform, used by 650,000 U.S. physicians, and has secured significant seed funding for expansion, but Viz.ai's established widespread deployment suggests a higher degree of current enterprise readiness.

Both tools demonstrate significant innovation in their respective domains. Viz RV/LV innovates by automating RV/LV ratio measurements from CTPA scans for rapid PE risk stratification and integrating it into a comprehensive care coordination platform. EchoNext is groundbreaking for its ability to detect a wide range of hidden structural heart diseases from standard ECGs, often outperforming human cardiologists, and has been described as the world's first FDA-approved AI detection tool for this purpose. Both represent substantial advancements in cardiology AI.

Viz.ai offers a comprehensive support system including a knowledge base, in-app support, email, and 24/7 urgent phone support. They also provide a Trust Center with direct access to extensive documentation for security and privacy. Pathway Labs (EchoNext) provides API docs, troubleshooting guides, GitHub issues, and a Discord community, along with email and text support, which is good for developers and technical users, but Viz.ai's offerings appear more tailored for broader clinical user support and compliance documentation.